Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics Limited has announced a change in the director’s interest, specifically regarding Miles Prince, who has acquired 4,273,142 ordinary shares indirectly through an on-market trade. This acquisition could potentially impact the company’s market perception and investor confidence, as it reflects a significant investment by a key director, signaling confidence in the company’s future prospects.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is listed on the Australian Securities Exchange (ASX) under the ticker CHM.
Technical Sentiment Signal: Sell
Current Market Cap: A$11.39M
See more insights into CHM stock on TipRanks’ Stock Analysis page.